

Attention Deficit Hyperactivity Disorder (ADHD)

Clinically proven alternatives for treating inattention, hyperactivity, and impulsivity

Abstract

The goal of this paper is to present an objective, up-to-date evaluation of the existing data and research as it pertains to Attention Deficit Hyperactivity Disorder (ADHD). Given the rapid expansion of the field and the associated data and literature, the hope is to help healthcare professionals synthesize current knowledge on ADHD and improve their ability to think critically about the condition. The aim is to provide insight that extends beyond the context of what may be seen in individual clinics and to provide valuable and current information on the pros and cons of existing main line treatments and other potential adjunctive or stand-alone options.

What is ADHD?

ADHD is a neuropsychiatric disorder characterized by symptoms of inattention with or without evidence of impulsivity and hyperactivity.¹ Historically, ADHD has been widely recognized and described as a condition affecting school-aged children, but it is now increasingly accepted as a valid diagnosis in adults as well. Several recent studies have shown that symptoms and impairments related to childhood ADHD can persist into adulthood, either wholly or partially.²

ADHD is a chronic condition in children that can start at 2 to 4 years of age and is composed of a persistent pattern of hyperactivity, impulsiveness, and a lack of focus. Importantly, in ADHD, these symptoms are more frequent than is usual for age-matched children and result in significant deficiencies in school or work performance, as well as in daily activities.³ ADHD is one of the most common neurodevelopmental disorders of adolescents and children, and it imparts social and economic burdens on the health system and on society.⁴ The Global Burden of Disease Study in 2010 reported estimates of 26 million children and adolescents with ADHD worldwide and 491,500 disability-adjusted life years.⁵

Critics of the concept of ADHD claim that it is not a clear-cut psychiatric disorder but is instead a scapegoat for the social stigma attached to children who are behaviorally difficult. The current argument is that ADHD is a descriptive diagnosis where the severity of behavior allows it to be differentiated from normal behavior. Importantly, those on each side of the argument about the legitimacy of ADHD agree that both over-diagnosis and under-diagnosis occur frequently.^{6,7}

How Often and by Whom is ADHD Diagnosed?

Though physicians or clinical psychologists are responsible for official ADHD diagnoses, teachers have taken on an increasingly larger role as “disease spotters.”⁸⁻¹⁰ In a review of 491 primary care doctors who had diagnosed ADHD in Washington, D. C., almost half of these diagnoses in children had first been ‘suggested’ by teachers. A teacher was the most likely person to be the first to recommend a ‘diagnosis’ of ADHD. Whereas 46.4% of ADHD diagnoses were first recommended by a teacher, only 30.2% were first recommended by a parent. Shockingly, only 11.3% of these cases were first identified as potential ADHD cases by physicians.¹¹ Thus, teachers seem to have become the primary diagnosticians of ADHD in children.

The teacher’s role as the diagnostician has been investigated more for ADHD than for any other disorder affecting children. The most recent version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), DSM-V, assigns teachers an active role in ADHD diagnosis by using assessment instruments such as the Conners’ Teacher’s Rating Scale, which incorporates teacher reports of behavior into clinicians’ diagnoses.¹²

As part of their role in diagnosing ADHD, teachers have also become responsible for explaining the disorder to parents and guiding parents and children through the diagnosis and treatment process. In the U.S., there are resources for teachers, including educational programs offered by the organization known as Children and Adults with Attention Deficit/Hyperactivity Disorder (CHADD).¹³⁻¹⁵ CHADD is the U.S.’s largest advocacy group for ADHD-affected persons. It acts as the chief editorial consultant of a special issue on ADHD in *Health in Action*, a publication of the American School Health Association.¹⁶

Between 2004 and 2005, 22% of CHADD’s total revenue was provided by the pharmaceutical industry,¹³ which may contribute to the surprising observations that ADHD is diagnosed in the U.S. more than in European countries and that those rates are increasing. Recent data have also shown that children born in August are more frequently diagnosed with ADHD than children born in September. Because September 1 tends to be the cut-off for kindergarten entry, those born in August are the youngest in their classes and thus likely the farthest behind developmentally and behaviorally.¹⁷ Experts suggest that these younger children are prone to misdiagnosis of ADHD as a result of what are actually normal behaviors for their age. This phenomenon has recently garnered widespread attention, with an opinion piece on the topic published by health policy researchers in late 2018 in the *New York Times*.¹⁸

How is ADHD Treated, and are Treatments Safe and Effective?

STIMULANT DRUGS – WHAT ARE THEY

Stimulant drugs are the first-line therapy for ADHD for both children and adults. Several studies indicate that these drugs, which include amphetamines, methamphetamines, and methylphenidate, are beneficial in helping to mitigate ADHD symptoms. However, the literature on the long-term safety, side-effects, and efficacy of these drugs is controversial. Treatment of ADHD with psychostimulants is criticized because stimulants pose direct health risks as well as the risk for addiction, and because there is evidence that the extent of the side-effects is underestimated.¹⁹⁻²¹

Amphetamines and Methamphetamines

Amphetamines and the related stimulants, methamphetamines, achieve at least some of their effects on ADHD by boosting the transmission of both dopamine and norepinephrine in the prefrontal cortex.^{22,23} These drugs act directly on dopamine and norepinephrine transporters by serving as pseudo-substrates at the binding sites of these transporters.²⁴ They also increase dopamine release that occurs in response to stimuli from the environment and enhance the release of catecholamines.^{22,24,25}

Methamphetamines, known also by the trade names Desoxyn and Methedrine, are available as oral tablets that are generally taken once or twice a day. They are not widely prescribed and are only approved for use against ADHD and obesity.²⁶

Compared to methamphetamines, there are many more prescription options for amphetamines, which come in immediate and extended release tablets, as well as in solution form. Two of the amphetamine brands that are available in both immediate and extended release form are Adderall and Dexedrine.

Adderall

Adderall and Adderall XR are immediate and extended release amphetamine medications, respectively.²⁴ The immediate release Adderall is formulated with amphetamine as tablets, which are available in 5 milligram (mg), 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, and 30 mg doses. The extended release version, which combines amphetamine and dextroamphetamine, comes as a capsule, which may be 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg.

A meta-analysis of the use of Adderall has suggested that it can improve symptoms of inattention, hyperactivity-impulsivity, and aggression.²⁷ However, some studies on the effect of Adderall have found that nearly one quarter of study participants given the drug did not respond to it.²⁸ Additionally, the drug poses concerns related to psychological events like psychosis, slowed growth in children, and substance abuse in adolescents and adults.²⁹

Dexedrine

Dexedrine, a dextroamphetamine tablet formulation, is an immediate release amphetamine, and Dexedrine SR, an amphetamine capsule, is an extended release option.²⁴ Both forms have 5 mg and 10 mg formulations, and Dexedrine SR also has a 15 mg option.

Research has indicated that Dexedrine is not prescribed as frequently as other ADHD medications. Nonetheless, comparative studies have shown that it can be as effective as other medications in treating symptoms of ADHD but also suffers some of the same limitations.³⁰

Other Immediate Release Amphetamines

Some amphetamine brands are only available as immediate release medications.²⁴ These include Evekeo, Dextrostat, and Zenzedi, all of which are offered as 5 mg and 10 mg tablets, as well as Procentra, which is a 5 mg/milliliter (mL) solution. Zenzedi has additional 2.5 mg, 7.5 mg, 15 mg, and 20 mg options as well.

Each of these immediate release amphetamines has been shown to improve ADHD symptoms.³¹ There are data suggesting that these drugs can be well-tolerated and that their efficacy can last throughout the day.^{32,33} Nonetheless, these drugs are also associated with some adverse side effects, such as anxiety, reduced appetite, headache, irritability, and abdominal pain.^{32,34}

Other Extended Release Amphetamine Drugs

As with immediate release amphetamine therapies, there are also brands that offer only extended release options.²⁴ Adzenys XR is an amphetamine formulated as an orally disintegrating tablet, which comes in the following mg doses: 3.1, 6.3, 9.4, 12.5, 15.7, and 18.8. Dyanavel XR is offered as a 2.5 mg/ML suspension, and Vyvanse – the only U.S. Food

and Drug Administration (FDA) approved lisdexamfetamine – comes in capsules that differ by 10 mg and range from 20 mg to 70 mg.

These drugs have been shown to reduce symptoms of ADHD in children, even as young as preschool age. They have also been shown in certain studies to be well-tolerated.^{35,36}

Methylphenidate

Methylphenidate is another stimulant used to treat ADHD, and it blocks the reuptake of both dopamine and norepinephrine. More specifically it works on central adrenergic brain cells by inhibiting presynaptic dopamine transporters, enhancing the concentration of dopamine in the synaptic cleft and thus increasing dopamine neurotransmission.²³ The drug has a similar action on the norepinephrine system, but its influence is not as strong as it is on the dopaminergic system.²⁴

As is the case with amphetamines, methylphenidate drugs are offered in both immediate release and extended release formulations.³⁷ The brands Ritalin and Methylin offer both types of formulation. The brand Focalin offers a formulation of dexamethylphenidate, which is similar to methylphenidate, in both immediate release and extended release varieties. The immediate release is available in 2.5 mg, 5 mg, and 10 mg tablets, and the extended release comes in capsules of 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg. The drug is also provided through a transdermal patch with the brand name Daytrana.^{38,39} The patch initially administers 10 mg of methylphenidate each day but can be titrated to 15 mg, 20 mg, and 30 mg doses.

Ritalin

Ritalin, which is the most recognizable methylphenidate brand, comes in immediate release tablets that may be 5 mg, 10 mg, or 20 mg. The extended release medications, Ritalin SR and Ritalin LA, come in a 20 mg tablet or a capsule that can be 20 mg, 30 mg, or 40 mg.²⁴

Ritalin appears enhance cognitive performance by modulating neuronal activity in brain networks involved in attention.⁴⁰ Though it may be sufficient to achieve certain outcomes in ADHD patients, it should be noted that it is not necessary. For instance, a recent study showed that while combining non-pharmacological with Ritalin in children with ADHD more efficiently improved behavior, the non-pharmacological approaches alone were also effective.⁴¹

Though Ritalin has held a place as a mainstay treatment for ADHD, there is significant tension in the medical community around its use.⁴² Of particular concern is the potential for substance abuse. As Ritalin prescribing frequency has increased, so too has abuse of the drug.⁴³ When taken intranasally, the effects of Ritalin are much like those of cocaine, in terms of both their type and their rapid onset.

Methylin

Methylin tablets are offered as both immediate release and extended release medications in 10 mg and 20 mg doses. Immediate release options also include a 5 mg tablet, chewables that comes in 2.5 mg, 5 mg, and 10 mg doses, as well as a solution offered in 5 mg/mL and 10 mg/ML doses.²⁴ Given that methylin is another formulation of methylphenidate, its risks and limitations mimic those of Ritalin.

Other Extended Release Methylphenidate Drugs

There are several other methylphenidate brands that offer only extended release formulations. These include Metadate ER, Metadate CD, Quillivant XR, Quillichew ER, and Concerta. These extended release drugs have been shown to reduce symptoms of ADHD in children and adolescents.^{44,45} Data suggest that these medications can combat symptoms in the morning, afternoon, and evening, and that they may be well-tolerated.⁴⁶ Though these drugs are similar to Ritalin, it is generally assumed that they are less likely to be abused or suffer from dosing limitations because of their extended release nature.⁴⁷

STIMULANT DRUGS – WHAT ARE THE RISKS?

Psychosis

While each stimulant drug carries its own risks, all stimulants increase children's likelihood of experiencing psychosis and other psychiatric challenges.⁴⁸ In addition, stimulants have been associated with the development of stuttering,⁴⁹ and new data show that these drugs affect the brain development.⁵⁰

Somatic Disease

In addition to psychiatric diseases, stimulants likely contribute to the heightened risk amongst those with ADHD for other somatic diseases.⁵¹ Indeed, psychostimulants used to treat ADHD have been shown to increase both heart rate and blood pressure.⁵² Specifically, those taking psychostimulants for ADHD have experienced rises in heart rate of 3 to 10 beats per minute, rises in systolic blood pressure of 3 to 8 mmHg, and rises in diastolic blood pressure of 2-14 mmHg. Whereas some of those with ADHD diagnoses are known to abuse stimulant drugs, these drugs are also abused by adolescents and adults who have not been diagnosed with ADHD.¹⁹ Although meta-analyses of children and adolescents diagnosed with ADHD and treated with psychostimulant drugs show less risk of future substance abuse, the same is not true for adults diagnosed with ADHD and treated with psychostimulants.^{53,54} On the contrary, an ADHD diagnosis is a risk factor for substance abuse in adults. Other psychiatric conditions increase this risk. New data also show that childhood methylphenidate use increases the likelihood of using antidepressants in adolescence.⁵⁵

Tolerance

Higher doses of stimulant drugs used to treat ADHD exacerbate the side effects. Unfortunately, increasingly higher doses are often needed as those taking these drugs develop tolerances to them.⁵⁶⁻⁵⁸ Indeed, the Multimodal Treatment Study of Children with ADHD (MTA), the largest ADHD treatment study in history, found that psychostimulants have less efficacy over time. According to the data, there are people who have been taking psychostimulants for years who have the same symptom levels as ADHD patients who have never taken medication for their disorder.⁵⁷

This apparent need for higher psychostimulant dose over time has led the American Academy of Child and Adolescent Psychiatry (AACAP) to recommend dose increases as needed. Their guidelines state that most children will eventually need higher drug doses during the course of their treatment. Of particular concern, though, is that because low brain dopamine levels are believed to be the cause of ADHD, decreasing the brain's sensitivity to dopamine is just the opposite of what ADHD patients need and could theoretically lead to the worsening of ADHD symptoms.⁵⁹

Eating Disorders and Insomnia

Also problematic is that most of the efficacious (higher dose) psychostimulants are associated with anorexia, weight loss, and insomnia.^{58,60} In children with ADHD, higher doses of methylphenidate are associated with parent ratings of increased insomnia and decreased appetite.⁶¹ Recent research has also begun to demonstrate the potential cognitive handicap provided by methamphetamines that may prevent normal cognition from developing and lead to impaired cognitive performance in those taking these drugs.⁶²

Poorer School Performance Teachers too likely see the effects of higher doses of methylphenidate. A 2017 Netherlands study of methylphenidate use in children confirms earlier studies of long-term drug failure and concludes that the use of methylphenidate is associated with poorer school performance.⁶³⁻⁶⁷ Though the evidence that long-term use of methylphenidate use impairs student performance contradicts earlier positive reports of the drug's effects, these more recent studies involve longer timeframes and larger study populations,⁶³⁻⁶⁷ making them potentially more credible.

A recent study in Europe examining the treatment emergent adverse events (TEAEs) in children and adolescents with ADHD using amphetamine drugs found that 89% of the participants reported TEAEs, with nearly 1 in 10 participants experiencing a serious TEAE.⁶⁸ Those TEAEs included:

- Increases in systolic blood pressure and diastolic blood pressure, which were reported by 22.4% and 38.8% of participants, respectively.
- Reductions in appetite, which occurred in nearly half the participants, and weight loss, experienced by 18.2% of the participants.

Interestingly, 31% of adults in the U.S. diagnosed with ADHD were prescribed amphetamines, while only 9.4% of European adults diagnosed with ADHD were given amphetamines.⁶⁹ It is therefore important to consider the underlying reasons for this distinction in amphetamine prescription rate for ADHD and what insights can be gleaned from comparative analyses of the relevant outcomes.

NON-STIMULANT DRUGS

In cases where the person with ADHD or their family members do not want to pursue stimulant drugs as a treatment option, or where stimulant drugs are contraindicated, poorly tolerated, or do not invoke an adequate clinical response, non-stimulant drugs may be prescribed. These drugs tend to work via presynaptic mechanisms related to catecholaminergic system.⁷⁰ Atomoxetine (ATX), guanfacine (GXR), and clonidine are three non-stimulant drugs that have been approved by the FDA for the treatment of ADHD. These drugs are also known by their trademark names: Strattera, Intuniv, and Kapvay, respectively.⁷¹ In addition to these non-stimulant drugs, people with ADHD are also sometimes prescribed medications that are conventionally used for depression. *Strattera*

Strattera, which is a selective norepinephrine reuptake inhibitor, was the first nonstimulant that was approved for the treatment of ADHD in the U.S. and is indicated as a monotherapy for adults as well as children who are at least 6 years of age. Dosing is variable, but the maximum daily dose for children and adolescents weighting up to 70 kilograms (kg) that is approved by the FDA is 1.4 mg/kg. For anyone weighting over 70 kg, the approved dosage is up to 100 mg per day.⁷² Though 80 mg per day has been

recommended for adults with ADHD, actual use by people with a prescription for Strattera appears to be, on average, about 60 mg per day.⁷³

This drug has been shown to reduce ADHD symptoms within the first week of treatment.⁷² This non-stimulant drug is also associated with improved morning and evening behavior related to ADHD in children. Another benefit of Strattera is that, unlike stimulant drugs, it does not have positive reinforcing effects and so is not associated with addiction.⁷⁴

Though the mechanism of action of Strattera is unclear, Strattera is known to be highly selective for and have high affinity to norepinephrine transporters and have been shown to suppress the uptake of norepinephrine.⁷⁵ It is therefore generally thought that its effects in patients with ADHD relates to its ability to increase levels of norepinephrine in the prefrontal cortex.

Strattera can lead to some adverse side-effects. For adults and children who experience side-effects, both nausea and reduction in appetite are common. Children with adverse side-effects also frequently experience abdominal pain and headaches, whereas adults with side-effects may endure insomnia, dry mouth, or erectile dysfunction.⁷²

Intuniv

Sometimes used in combination with Strattera, Intuniv is a selective adrenergic-receptor agonist in an extended release formulation.⁷⁶ Like Strattera, it is also indicated as a monotherapy but only for youths aged 6 to 17. However, a recent randomized, double-blind, placebo-controlled trial published in *the Journal of Clinical Psychiatry*, showed for the first time that guanfacine extended-release significantly improved ADHD symptoms in adults and that the drug tended to be safe.⁷⁷

In this study, 101 adult ADHD patients were given titrated doses of the drug starting at 2 mg per day and moving to 4 mg and 6 mg per day, while 100 adult ADHD patients were given placebo. After 5 weeks of dose optimization, drug doses were tapered. Patients who took the guanfacine extended-release displayed significantly greater improvements in the Japanese version of the ADHD-Rating Scale-IV than did those taking placebo. These improvements were seen in overall scores as well as in sub-scores on inattention and hyperactivity.

Though Intuniv has been shown to improve ADHD symptoms in in both the morning and evening,^{78,79} there have been no studies that directly compare the efficacy of Intuniv to other active treatments, and indirect analyses provide inconsistent views on the relative efficacy of Intuniv.⁸⁰ Additionally, studies have shown that Intuniv does not successfully overcome certain symptoms of ADHD, such as impulse control.⁸¹

It may be the case that the value of Intuniv derives from its superior effects in specific contexts. For instance, some data suggest that Intuniv may help children with co-morbidities like chronic tic disorders or oppositional symptoms who have not been responsive to other treatments.⁸²

This drug, which is available in 1 mg, 2 mg, 3 mg, and 4 mg tablets, appears to work by stimulating postsynaptic adrenergic receptors and enhancing signaling of pyramidal neurons of the prefrontal cortex.^{70,83} The result of this modification to neural activity is often improved memory and attention.

In addition to questions over the efficacy of Intuniv, it is also unclear how safe the drug is. While some studies have found Intuniv to be well-tolerated,⁷⁸ with the most commonly reported adverse side-effects being fatigue and headache,⁸⁴ other studies have identified more concerning undesirable side-effects, including hypotension, sedation, and bradycardia, and found that these side-effects are common.⁸⁰

Research has shown that the side-effects associated with Intuniv can limit its tolerability and that discontinuing the drug can also lead to troubling symptoms, such as rebound hypertension and tachycardia, particularly if Intuniv use is abruptly discontinued. Further complicating our understanding of the impact of Intuniv is that its mechanism of action in ADHD is unclear.

Kapvay

Kapvay can serve as both a monotherapy and as an adjunctive therapy for those with ADHD. Though there is relatively little coverage of the use of Kapvay ADHD in the medical literature, the data thus far suggest that Kapvay is associated with improved sleep duration, and like other non-stimulant drugs, Kapvay may be well-tolerated.⁸⁵

An alpha-2 adrenergic agonist, Kapvay is thought to influence ADHD symptoms by enhancing noradrenergic sympathetic transmission and thereby improving functioning in areas of the prefrontal cortex that are critical for attention and behavior.⁸⁶ While Kapvay can improve certain symptoms of ADHD, it is also associated with side effects, the most common of which appears to be somnolence.⁸⁷ ADHD is also associated with headache, hypotension, bradycardia, and clinically significant changes in electrocardiographic results.⁸⁶ The drug is available as 0.1 mg tablets.⁸⁸

A recent study showed that the primary driver for prescribing this drug over other ADHD medications was its cost-effectiveness. The second most common reason this drug was prescribed was because the patient had a history of seizures, which is a contraindication for methylphenidate.⁸⁹ Interestingly, the authors of this study found that nearly one quarter of all children who took this non-stimulant medication experienced sedation, which may account for what in other studies has been interpreted as improved sleep

duration. Withdrawal syndrome is also common for those who abruptly stop taking Kapvay. Withdrawal has been observed in up to 80% of these cases.⁹⁰

Antidepressant Drugs

Though they have been shown to be less effective than stimulant medications in treating ADHD symptoms like those related to attention and cognition, antidepressants are sometimes used to address hyperactivity and impulsivity in ADHD patients and likely achieve at least some of their effects via their influence on the dopamine system.⁹¹ In the case that antidepressants are prescribed, the patients are likely to be refractory to stimulant drugs.⁹² While antidepressants are limited in what they can do for ADHD patients, they also pose the same risks that they do for patients who take them for depression.

NON-PHARMACOLOGICAL ALTERNATIVE TREATMENTS Although pharmacological treatments for ADHD symptoms for most children work in the short-term, 20 to 30% of children are non-responders or cannot tolerate the side-effects of these drugs. The same is true for adults diagnosed with ADHD.^{93,94}

According to a 1999 survey, parents of 64% of children with ADHD chose non-prescription alternative medicine treatments to address their children's ADHD.⁹⁵ Research shows that alternative therapies are as effective as prescription drugs, with a slight trend towards more effective results in the non-prescription group.^{95,96} Alternative therapies are discussed below.

Sleep

Both children and adults diagnosed with ADHD demonstrate unhealthy sleep patterns, and any comprehensive treatment regimen must not only help to reduce ADHD symptoms of poor concentration, poor focus, impulsivity, and hyperactivity but must also help to correct and reestablish better sleep patterns.^{97,98} Indeed, healthy sleep patterns are crucial to successful long-term ADHD intervention and overall long-term health as well.

Technology

Though alterations to sleep and dietary intake appear to be the most promising non-pharmacological ways to improve ADHD symptoms, new technologies are also being developed to address the disorder. For instance, a new device aimed at helping those with ADHD by delivering low-level electrical pulses to targeted areas of the brain, has recently been approved by the FDA.⁹⁹

There has been a wealth of research on the impact of dietary ingredients on different aspects of ADHD and related symptoms. New data have shown that when children with ADHD are treated with micronutrients or medication, ADHD symptoms improve. However, unlike with medication, children using micronutrients to address their ADHD symptoms do not experience deteriorations in their moods and anxiety.¹⁰⁰

Though nearly 20% of those diagnosed with ADHD in Europe are given dietary supplements, supplements are given to only 10% of U.S adults diagnosed with ADHD. Remarkably, in the U.K. alone, 27.7% of ADHD patients are given supplements – almost three times as many as in the U.S.⁶⁹

Below is a list of supplements whose use in the management of ADHD are supported with clinical data and that have the potential to work well together as a stand-alone cocktail treatment or adjunctively in patients who take pharmacological treatments.

Bacopa Monnieri Extract

Bacopa monnieri extract, or Brahmi, is a traditional Indian medicinal plant that has multiple effects on the central nervous system. Standardized extracts of this plant have been shown to enhance information processing in healthy volunteers, and improvements in memory-impaired adults.^{101,102} Recent research has shown that the substance can provide neuroprotection and improve cognitive deficits.^{103,104} Indeed, its impact on Alzheimer's disease pathology has led researchers to suggest that it may contribute to an effective drug treatment for Alzheimer's and other forms of dementias.^{105,106}

In one study, 31 children previously diagnosed with ADHD were given 225 milligrams (mg) of Bacopa monnieri extract daily for a total of 6 months. Symptoms of attention deficits were improved in 85% of the children. More than half of the children experienced reductions in impulsivity and psychiatric disturbances. In addition, learning improvements occurred in 78% of the children.⁵⁵

In 2000 and 2002, two other studies were published that looked at the impact of Bacopa monnieri in children previously diagnosed with ADHD. The data from these studies corroborate the finding that Bacopa monnieri improves ADHD symptoms.^{67,107}

A new and comprehensive literature survey has helped to clarify these beneficial impacts of Bacopa monnieri. Bacopa monnieri appears to work through several signaling pathway to mitigate harmful oxidative stress.¹⁰⁸

Magnesium Alone and Magnesium – Vitamin B6 Combinations

Magnesium levels are demonstrably lower in children diagnosed with ADHD, as evidenced by measures of magnesium collected from the hair, nails, and blood serum of these children.⁵⁸ Indeed, recent meta-analyses based on exhaustive literature reviews corroborated this point.^{109,110} Whether magnesium supplementation can alleviate ADHD symptoms has thus been of interest among ADHD researchers.

A study of 50 children diagnosed with ADHD and who were also deficient in magnesium examined the impact of 200 mg supplementation of elemental magnesium over a 6 month period.¹¹¹ Compared to the children who did not receive magnesium supplementation, those taking the magnesium developed higher levels of magnesium in their hair, which was accompanied by a significant reduction in hyperactivity.

Recent research into the role of nutrition on ADHD has also shown that magnesium appears to influence the gut microbiome in a way that could impact ADHD symptoms.¹¹² While magnesium supplementation reduces the symptoms of ADHD in children with the disorder, supplementation with a combination of magnesium and vitamin B6 has been shown to lower ADHD symptoms even further.^{111,113-115} These findings are perhaps unsurprising given that disorders of vitamin B6 metabolism are common among those with ADHD.¹¹⁶

Data shows that not only does a magnesium-B6 regimen significantly reduce clinical signs of ADHD, but when the regimen is terminated, the symptoms reappear within a few weeks.¹¹⁴ One study on 40 children with ADHD showed that 8 weeks of a magnesium-B6 regimen reduced ADHD symptoms including hyperactivity, aggressiveness, and inattention.¹¹⁴ Similarly, another study on 52 children with the disorder found that 1 to 6 months of a magnesium-B6 combination reduced the same symptoms, as well as hypertension, myoclony, and spasm.¹¹⁵

Vitamin D

Research has shown that vitamin D deficiency is more common in ADHD patients than in healthy controls.^{64,65} One study found that 64% of ADHD patients were not only deficient in vitamin D but were moderately or severely deficient, with serum levels between 10 and 20 nanograms per milliliter (ng/mL) or below 10 ng/mL, respectively.⁶⁶ A more recent comprehensive meta-analysis covering data from over 11,000 children also found that children with ADHD have significantly lower levels of vitamin D than those without ADHD.⁶³

A 2018 study helped to clarify the mechanism responsible for lower vitamin D levels, as it revealed that children with ADHD not only had lower serum vitamin D levels but also lower

vitamin D receptor levels.¹¹⁷ This study was the first to compare vitamin D receptor levels in those with and without ADHD. More recent research has also suggested that vitamin D may impact ADHD through its effects on dopamine levels.¹¹⁸

The first study to measure the effects of vitamin D supplementation and its effects on ADHD found that supplementation improves cognitive function, inattention, hyperactivity, and impulsivity.¹¹⁹ A recent double-blind, randomized clinical trial also showed that oral vitamin D improves symptoms of ADHD, particularly symptoms of inattention, and that it is especially beneficial for those who previously had insufficient levels of vitamin D.¹²⁰ Another recent study showed that vitamin D supplementation also improves ADHD symptoms without serious adverse side effects in those who also take methylphenidate for their ADHD.¹²¹

L-Theanine

L-Theanine is an amino acid that is present in significant amounts in green tea. This compound has been found to have a calming effect and is used to improve cognitive and mental performance.^{122,123} Alpha-wave predominance in the brain is associated with a state of relaxation, and people experience a shift toward more alpha-wave production within 40 minutes of taking 50 to 200 mg theanine doses. The effects appear to last up to eight hours and are dose-dependent.^{124,125} A double-blind, placebo-controlled study on boys diagnosed with both ADHD and sleep disorders also demonstrated that L-theanine significantly increases sleep efficiency as well as time spent asleep.¹²⁶

Grape Seed Extract

Grape seed extract is one of the most potent antioxidant extracts from plant sources, even more potent than pine bark extract,¹²⁷ providing, for instance, excellent protection against oxidative stress and free radical-driven tissue injury.¹²⁸

Grape seed is highly bioavailable and provides greater protection against free radicals and damage to cell membranes and DNA than vitamins C and E, when the vitamins are taken individually or in combination. Scientific studies have shown that the antioxidant power of proanthocyanidins is 20 times greater than that of vitamin E and 50 times greater than that of vitamin C.¹²⁹

Children diagnosed with ADHD demonstrate higher levels of lipid peroxides than do controls and are at greater risk for developing cardiovascular disease.¹³⁰⁻¹³² Potent antioxidants like grape seed extract that provide protection against excessive oxidative stress and cardiovascular risk factors are therefore likely to be beneficial for those with ADHD.^{133,134}

Vitamin C

Vitamin C is the most prevalent water-soluble antioxidant in the human body.¹³⁵ It inhibits the first step in developing coronary artery disease - LDL-cholesterol oxidation - and plays a major role in other protective mechanisms against heart disease, such as lowering C-reactive protein.¹³⁵ Vitamin C may therefore help to mitigate the enhanced cardiovascular risks that ADHD patients experience.¹³⁵⁻¹³⁷ Because humans cannot synthesize vitamin C, they must get this critical vitamin from their diets.^{136,137} As such, supplementation is often necessary for adequate vitamin C consumption, which may be the case for some of those with ADHD.

Iron

Recent studies have found an association between ADHD and iron deficiency.¹³⁸ Children with more severe iron deficiencies are more likely to also experience more severe ADHD symptomology,¹³⁹ and iron deficiency in infancy has been shown to be predictive of social and behavioral problems in adolescence.¹⁴⁰ Lower serum ferritin levels are correlated with more severe ADHD symptoms as measured by the Conners' Parent Rating Scale.¹⁴¹ Iron deficiency has not only been observed in children with ADHD but has also been shown to be higher in adults with ADHD than in those without the disorder.¹⁴² Interestingly, people with restless leg syndrome (RLS) also often display low levels of ferritin, and those with RLS are more likely to also have ADHD.¹⁴³

Based on these findings, it has been suggested the iron supplementation may reduce symptoms of ADHD, and there is evidence that such supplementation is effective.¹⁴⁴ Iron supplementation that leads to higher levels of blood iron is also associated with better performance on the Conners' Parent Rating Scale.¹⁴⁵ In one study, researchers provided children with 80 mg of iron per day and found that this iron supplementation improved ADHD symptoms. According to this study, iron therapy was also well tolerated.¹⁴⁶

Lemon Balm Extract

Lemon balm, or *Melissa officinalis*, has been used as an anti-anxiety, sleep-inducing, and memory-enhancing nutrient for over 2,000 years.¹⁴⁷ Human trials have provided scientific evidence for the impact of lemon balm, demonstrating its ability to improve mood, reduce stress, and help induce sleep.¹⁴⁸⁻¹⁵⁰ For instance, one study that investigated the impact of lemon balm extract on 20 stressed volunteers over a 15 day period found that anxiety was reduced in 70% of the study participants and insomnia was reduced in 85% of them.¹⁵⁰ Given that ADHD patients often experience stress and suffer from a high rate of insomnia, lemon balm extract is likely a helpful supplement for these patients.

Melatonin

The role of melatonin, a pineal gland hormone, has been studied in patients who suffer from sleep disorders, including insomnia, delayed sleep onset, and nighttime awakening issues.¹⁵¹ One study showed that when children took melatonin supplements at bedtime, they were able to fall asleep faster and also experienced additional health and behavioral benefits.¹⁵² Further, once the melatonin was discontinued, the children's sleep and behavioral problems returned. The positive effects of melatonin are corroborated by earlier trials in children with ADHD, which help to confirm that melatonin is effective in treating insomnia.¹⁵³⁻¹⁵⁵

Zinc Sulfate

Zinc deficiency appears to contribute to the etiology of ADHD.¹⁵⁶ Over the course of a 6 week double-blind study of 44 children previously diagnosed with ADHD, zinc sulfate supplementation, given as an adjunct to methylphenidate, improved ADHD symptoms.¹⁵⁷ Other research on the impact of zinc on those with ADHD over an 8-week period suggests that a daily dose of 30 mg is effective in reducing the amount of amphetamine needed to treat ADHD and that this dosage is well-tolerated and safe.¹⁵⁸

Crocus Sativus

There is evidence to suggest that crocus sativus, also known as saffron, can be beneficial to those with ADHD. Specifically, crocus sativus has been shown to be as effective as methylphenidate in improving ADHD symptoms over a 6-week period, as measured with the Teacher and Parent Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV).^{159,160}

Omega-3 Fatty Acids

Omega-3 deficiencies have been observed in those with ADHD.¹⁶¹ Even maternal consumption of omega-3 fatty acids has been implicated in the disorder.¹⁶² Though the evidence related to the influence of omega-3s on ADHD is mixed, certain studies suggest that multiple types of omega-3 fatty acids may be effective in treating ADHD symptoms in youths.¹⁶³ A 30-week study on omega-3 fatty acids demonstrated potential therapeutic effects on ADHD symptoms in children, particularly in those who are hyperactive-impulsive.¹⁶⁴ Some of the specific benefits that have been observed with omega-3 supplementation in those with ADHD are cognitive effects, including enhanced visual learning, reading, and memory, as well as improvements in hyperactivity, impulsivity, and attention.¹⁶⁵

Omega-3 supplementation appears to enable the reduction of stimulant medication doses in those with ADHD.^{165,166} Given this impact and the safety profile of omega-3s, experts have suggested that omega-3 supplementation may offer a suitable alternative to pharmacological interventions in those with ADHD.^{167,168}

Phosphatidylserine

Phosphatidylserine has been shown to improve ADHD symptoms in children, including symptoms related to cognition.¹⁶⁹ Some research suggests that phosphatidylserine supplementation may be particularly effective for ADHD children who are emotionally and behaviorally dysregulated.¹⁶⁴

Conclusion

Diagnosis and treatment are not as clear-cut with ADHD as they are with many other conditions. Treating ADHD has been criticized as being an inadequate substitute for good parenting and education. Critics claim that treatment medicalizes a psychosocial problem without curing the underlying cause and that the long-term effects of this treatment are thus limited. They argue that many of these treatments may even jeopardize the health of those diagnosed with ADHD.

There are also many people who believe that ADHD treatment and alteration of parenting styles are not mutually exclusive and that simultaneously pursuing both routes can help to achieve the best results for the children. For those who feel the need for a strategy that goes beyond behavioral modification, the treatment options can be overwhelming.

Choosing a treatment regimen is further complicated by social pressure and incomplete scientific information. Nonetheless, the science to support the value of nutraceuticals in the treatment of ADHD in both children and adults is growing. Not only can nutraceuticals be effective in improving ADHD symptoms, but they can help bypass the risks, such as addiction, as well as the unwanted side-effects associated with other treatment options.

I suggest that healthcare providers recommend to parents of minor children and to adults diagnosed with ADHD to use a “cocktail” of the nutraceuticals discussed in this paper either as an initial stand-alone therapy or adjunctively with prescribed medications. Given the risks associated with both stimulant and non-stimulant prescription drugs, there is good reason to attempt to control ADHD with non-prescription options before resorting to pharmaceutical methods. This notion is consistent with expert guidelines that recommend a stepwise approach to ADHD treatment that begins with non-drug interventions.¹⁷⁰

Unless behavioral problems are extreme enough to constitute emergency intervention, a cocktail of nutraceuticals should be tested over a 3 to 4-month period. This duration should be sufficient for achieving systemic levels of the included ingredients that are required for a therapeutic effect. During the time that the cocktail is used, sleep patterns should also be tracked so that any improvements can be noted. In particular, falling asleep faster, staying asleep longer, and sleeping for at least 8 hours (for adolescents) or 9 hours (for younger children) are signs of healthier sleep habits.

If after 3 to 4 months of the nutraceutical cocktail, more benefits are desired, then starting a drug-naïve ADHD child or adult on a prescription drug or adding a prescription drug to a previous regimen may be justified. Any time a new intervention is added, behavior should be tracked and documented to ensure that insights related to the impact of each intervention are captured. Collecting these types of data will enable those with ADHD to customize their treatment such that they can optimize their outcomes and manage their ADHD in accordance with their preferences.

References

1. National Institute for Health and Clinical Excellence. NICE Clinical Guidelines 72: Attention deficit hyperactivity disorder diagnosis and management of ADHD in children, young people and adults. 2008.
2. Faraone S V, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. *Psychol Med*. 2006;36(2):159-165. doi:10.1017/S003329170500471X
3. Feldman HM, Reiff MI. Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. *N Engl J Med*. 2014;370(9):838-846. doi:10.1056/NEJMcp1307215
4. Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. *J Pediatr Psychol*. 2007;32(6):711-727. doi:10.1093/jpepsy/jsm022
5. Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet (London, England)*. 2012;380(9859):2197-2223. doi:10.1016/S0140-6736(12)61689-4
6. Kooij SJJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. *BMC Psychiatry*. 2010;10:67. doi:10.1186/1471-244X-10-67
7. Rutter M. Research review: Child psychiatric diagnosis and classification: concepts, findings, challenges and potential. *J Child Psychol Psychiatry*. 2011;52(6):647-660. doi:10.1111/j.1469-7610.2011.02367.x
8. Phillips CB. Medicine goes to school: teachers as sickness brokers for ADHD. *PLoS Med*. 2006;3(4):e182. doi:10.1371/journal.pmed.0030182
9. Conrad P. Medicalization and social control. *Ann Rev Sociol*. 1992;18:209-232.
10. Conners C. Manual for the Conners' Rating Scales - revised. *Multi-Health Syst*. 1997.
11. Sax L, Kautz KJ. Who first suggests the diagnosis of attention-deficit/hyperactivity disorder? *Ann Fam Med*. 2003;1(3):171-174.

12. Swanson, JM, Wigal, T, & Lakes K. DSM-V and the future diagnosis of attention-deficit/hyperactivity disorder. *Curr Psychiatry Rep.* 2009;11(5):399-406.
13. CHADD. *CHADD Annual Report*.
http://www.chadd.org/pdfs/2005_Annual_Report.pdf.
14. CHADD. Reaching educators.
http://www.chadd.org/webpage.cfm?cat_id=10&subcat_id=77. Published 2004.
Accessed December 23, 2005.
15. Foggo D. ADHD advice secretly paid for by drug companies.
<http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2005/10/09/nadhd09.xml>. Published 2005.
16. Kidsonline. National Association of School of Nurses (NASN) supports educational program about management of attention deficit hyperactivity disorder (ADHD) in schools. 2006.
<http://www.kidsource.com/kidsource/content3/news3/adhd.nurses.html>.
17. Layton TJ, Barnett ML, Hicks TR, Jena AB. Attention Deficit-Hyperactivity Disorder and Month of School Enrollment. *N Engl J Med.* 2018;379(22):2122-2130.
doi:10.1056/NEJMoa1806828
18. Anupam B. Jena, Michael Barnett TJJ. The link between August birthdays and ADHD. *New York Times*. <https://www.nytimes.com/2018/11/28/opinion/august-birthdays-adhd.html>. Published November 28, 2018.
19. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. *J Am Acad Child Adolesc Psychiatry.* 2008;47(1):21-31. doi:10.1097/chi.0b013e31815a56f1
20. Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. *Pharmacol Biochem Behav.* 2001;68(3):611-627.
21. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. *Arch Gen Psychiatry.* 1995;52(6):456-463.
22. Briars L, Todd T. A Review of Pharmacological Management of Attention-Deficit/Hyperactivity Disorder. *J Pediatr Pharmacol Ther.* 2016;21(3):192-206.

doi:10.5863/1551-6776-21.3.192

23. Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. *Pharmacotherapy*. 2003;23(10):1281-1299. doi:10.1592/phco.23.12.1281.32697
24. Brown KA, Samuel S, Patel DR. Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners. *Transl Pediatr*. 2018;7(1):36-47. doi:10.21037/tp.2017.08.02
25. Jain R, Katic A. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder. *Prim care companion CNS Disord*. 2016;18(4). doi:10.4088/PCC.16r01979
26. Wood S, Sage JR, Shuman T, Anagnostaras SG. Psychostimulants and cognition: a continuum of behavioral and cognitive activation. *Pharmacol Rev*. 2014;66(1):193-221. doi:10.1124/pr.112.007054
27. Faraone S V, Biederman J. Efficacy of Adderall for Attention-Deficit/Hyperactivity Disorder: a meta-analysis. *J Atten Disord*. 2002;6(2):69-75. doi:10.1177/108705470200600203
28. Pelham WE, Aronoff HR, Midlam JK, et al. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder. *Pediatrics*. 1999;103(4):e43. doi:10.1542/peds.103.4.e43
29. Berman SM, Kuczenski R, McCracken JT, London ED. Potential adverse effects of amphetamine treatment on brain and behavior: a review. *Mol Psychiatry*. 2009;14(2):123-142. doi:10.1038/mp.2008.90
30. Ramtvedt BE, Roinas E, Aabech HS, Sundet KS. Clinical gains from including both dextroamphetamine and methylphenidate in stimulant trials. *J Child Adolesc Psychopharmacol*. 2013;23(9):597-604. doi:10.1089/cap.2012.0085
31. Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present--a pharmacological and clinical perspective. *J Psychopharmacol*. 2013;27(6):479-496. doi:10.1177/0269881113482532
32. Childress AC, Brams M, Cutler AJ, et al. The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-

- Controlled Crossover Laboratory Classroom Study. *J Child Adolesc Psychopharmacol*. 2015;25(5):402-414. doi:10.1089/cap.2014.0176
33. Coghill DR, Caballero B, Sorooshian S, Civil R. A systematic review of the safety of lisdexamfetamine dimesylate. *CNS Drugs*. 2014;28(6):497-511. doi:10.1007/s40263-014-0166-2
 34. Coughlin CG, Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Bloch MH. Meta-Analysis: Reduced Risk of Anxiety with Psychostimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol*. 2015;25(8):611-617. doi:10.1089/cap.2015.0075
 35. Childress AC, Findling RL, Wu J, et al. Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol*. 2020;30(3):128-136. doi:10.1089/cap.2019.0117
 36. Childress AC, Wigal SB, Brams MN, et al. Efficacy and Safety of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol*. 2018;28(5):306-313. doi:10.1089/cap.2017.0095
 37. Weisler RH. Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD. *Expert Opin Pharmacother*. 2005;6(6):1003-1018. doi:10.1517/14656566.6.6.1003
 38. Transdermal methylphenidate (Daytrana) for ADHD. *Med Lett Drugs Ther*. 2006;48(1237):49-51.
 39. Barnett R. Attention deficit hyperactivity disorder. *Lancet (London, England)*. 2016;387(10020):737. doi:10.1016/s0140-6736(16)00332-9
 40. Tremblay S, Pieper F, Sachs A, Joobor R, Martinez-Trujillo J. The Effects of Methylphenidate (Ritalin) on the Neurophysiology of the Monkey Caudal Prefrontal Cortex. *eNeuro*. 2019;6(1). doi:10.1523/ENEURO.0371-18.2018
 41. Pakdaman F, Irani F, Tajikzadeh F, Jabalkandi SA. The efficacy of Ritalin in ADHD children under neurofeedback training. *Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol*. 2018;39(12):2071-2078. doi:10.1007/s10072-018-3539-3
 42. Keane H. Pleasure and discipline in the uses of Ritalin. *Int J Drug Policy*. 2008;19(5):401-409. doi:10.1016/j.drugpo.2007.08.002

43. Morton WA, Stockton GG. Methylphenidate Abuse and Psychiatric Side Effects. *Prim Care Companion J Clin Psychiatry*. 2000;2(5):159-164. doi:10.4088/pcc.v02n0502
44. QuilliChew ER--extended-release chewable methylphenidate tablets. *Med Lett Drugs Ther*. 2016;58(1495):68-69.
45. Anderson VR, Keating GM. Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder. *Paediatr Drugs*. 2006;8(5):319-333. doi:10.2165/00148581-200608050-00005
46. Pliszka SR, Wilens TE, Bostrom S, et al. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol*. 2017;27(6):474-482. doi:10.1089/cap.2017.0084
47. Wigal SB, Childress A, Berry SA, et al. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol*. 2017;27(8):690-699. doi:10.1089/cap.2016.0177
48. Emery G. With ADHD, amphetamine has double the psychosis risk of methylphenidate. reuters.com. <https://www.reuters.com/article/us-health-adhd-adderall-psychosis/with-adhd-amphetamine-has-double-the-psychosis-risk-of-methylphenidate-idUSKCN1R12PR>. Published 2019. Accessed April 6, 2019.
49. Trenque T, Claustre G, Herlem E, et al. Methylphenidate and stuttering. *Br J Clin Pharmacol*. August 2019. doi:10.1111/bcp.14097
50. Bouziane C, Filatova OG, Schrantee A, Caan MWA, Vos FM, Reneman L. White Matter by Diffusion MRI Following Methylphenidate Treatment: A Randomized Control Trial in Males with Attention-Deficit/Hyperactivity Disorder. *Radiology*. August 2019:182528. doi:10.1148/radiol.2019182528
51. Akmatov MK, Ermakova T, Batzing J. Psychiatric and Nonpsychiatric Comorbidities Among Children With ADHD: An Exploratory Analysis of Nationwide Claims Data in Germany. *J Atten Disord*. July 2019:1087054719865779. doi:10.1177/1087054719865779
52. Fay TB, Alpert MA. Cardiovascular Effects of Drugs Used to Treat Attention Deficit/Hyperactivity Disorder Part 2: Impact on Cardiovascular Events and Recommendations for Evaluation and Monitoring. *Cardiol Rev*. December 2018.

doi:10.1097/CRD.0000000000000234

53. Faraone S V, Wilens T. Does stimulant treatment lead to substance use disorders? *J Clin Psychiatry*. 2003;64 Suppl 1:9-13.
54. Wilens TE. Impact of ADHD and its treatment on substance abuse in adults. *J Clin Psychiatry*. 2004;65 Suppl 3:38-45.
55. Madjar N, Shlosberg D, Leventer-Roberts M, et al. Childhood methylphenidate adherence as a predictor of antidepressants use during adolescence. *Eur Child Adolesc Psychiatry*. March 2019. doi:10.1007/s00787-019-01301-z
56. Ross DC, Fischhoff J, Davenport B. Treatment of ADHD when tolerance to methylphenidate develops. *Psychiatr Serv*. 2002;53(1):102. doi:10.1176/appi.ps.53.1.102
57. Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA study. *J Am Acad Child Adolesc Psychiatry*. 2007;46(8):989-1002. doi:10.1097/CHI.0b013e3180686d48
58. Swanson J, Gupta S, Guinta D, et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. *Clin Pharmacol Ther*. 1999;66(3):295-305. doi:10.1016/S0009-9236(99)70038-X
59. Yanofski J. The dopamine dilemma-part II: Could stimulants cause tolerance, dependence, and paradoxical decompensation? *Innov Clin Neurosci*. 2011;8(1):47-53.
60. Stein MA. Unravelling sleep problems in treated and untreated children with ADHD. *J Child Adolesc Psychopharmacol*. 1999;9(3):157-168. doi:10.1089/cap.1999.9.157
61. Ramtvedt BE, Aabech HS, Sundet K. Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate. *J Child Adolesc Psychopharmacol*. 2014;24(3):130-139. doi:10.1089/cap.2013.0114
62. Dean AC, Morales AM, Hellemann G, London ED. Cognitive deficit in methamphetamine users relative to childhood academic performance: link to cortical thickness. *Neuropsychopharmacology*. 2018;43(8):1745-1752. doi:10.1038/s41386-018-0065-1
63. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. Long-term school

- outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. *J Dev Behav Pediatr.* 2007;28(4):265-273. doi:10.1097/DBP.0b013e31811ff87d
64. Loe IM, Feldman HM. Academic and educational outcomes of children with ADHD. *J Pediatr Psychol.* 2007;32(6):643-654. doi:10.1093/jpepsy/jsl054
 65. Polderman TJC, Boomsma DI, Bartels M, Verhulst FC, Huizink AC. A systematic review of prospective studies on attention problems and academic achievement. *Acta Psychiatr Scand.* 2010;122(4):271-284. doi:10.1111/j.1600-0447.2010.01568.x
 66. Barry, T, Lyman, R, Klinger L. Academic under-achievement and attention deficit/hyperactivity disorder: the negative impact of symptom severity on school performance. *J Sch Psychol.* 2002;40:459-483.
 67. Wilens TE, Biederman J, Brown S, et al. Psychiatric comorbidity and functioning in clinically referred preschool children and school-age youths with ADHD. *J Am Acad Child Adolesc Psychiatry.* 2002;41(3):262-268. doi:10.1097/00004583-200203000-00005
 68. Coghill D et al. Long-term safety and efficacy of lisdexamfetamine dimesylate in children and adolescents with ADHD: A phase IV, 2-year, open-label study in Europe. *CNS Drugs.* 2017;31(7):625-638.
 69. Able SL, Haynes V, Hong J. Diagnosis, treatment, and burden of illness among adults with attention-deficit/hyperactivity disorder in Europe. *Pragmatic Obs Res.* 2014;5:21-33. doi:10.2147/POR.S64348
 70. Alamo C, Lopez-Munoz F, Sanchez-Garcia J. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (adhd). *Actas Esp Psiquiatr.* 2016;44(3):107-112.
 71. Sikirica V, Findling RL, Signorovitch J, et al. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology. *CNS Drugs.* 2013;27(11):943-953. doi:10.1007/s40263-013-0102-x
 72. Childress AC. A critical appraisal of atomoxetine in the management of ADHD. *Ther Clin Risk Manag.* 2016;12:27-39. doi:10.2147/TCRM.S59270

73. Clemow DB. Suboptimal dosing of Strattera (atomoxetine) for ADHD patients. *Postgrad Med.* 2014;126(5):196-198. doi:10.3810/pgm.2014.09.2814
74. Wee S, Woolverton WL. Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine. *Drug Alcohol Depend.* 2004;75(3):271-276. doi:10.1016/j.drugalcdep.2004.03.010
75. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. *Paediatr Drugs.* 2009;11(3):203-226. doi:10.2165/00148581-200911030-00005
76. Treuer T, Gau SS-F, Mendez L, et al. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. *J Child Adolesc Psychopharmacol.* 2013;23(3):179-193. doi:10.1089/cap.2012.0093
77. Iwanami, A. et al. Efficacy and safety of guanfacine extended-release in the treatment of attention-deficit/hyperactivity disorder in adults: Results of a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry.* 2020;81(3):e1-9.
78. Wilens TE, Robertson B, Sikirica V, et al. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry.* 2015;54(11):916-25.e2. doi:10.1016/j.jaac.2015.08.016
79. Wilens TE, McBurnett K, Turnbow J, Rugino T, White C, Youcha S. Morning and Evening Effects of Guanfacine Extended Release Adjunctive to Psychostimulants in Pediatric ADHD. *J Atten Disord.* 2017;21(2):110-119. doi:10.1177/1087054713500144
80. Harricharan S, Adcock L. Guanfacine hydrochloride extended release for attention deficit hyperactivity disorder: A review of clinical effectiveness, cost-effectiveness, and guidelines. *Ottawa Can Agency Drugs Technol Heal.* March 2018.
81. Fitzpatrick CM, Andreasen JT. Differential effects of ADHD medications on impulsive action in the mouse 5-choice serial reaction time task. *Eur J Pharmacol.* 2019;847:123-129. doi:10.1016/j.ejphar.2019.01.038
82. Huss M, Chen W, Ludolph AG. Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe. *Clin Drug Investig.* 2016;36(1):1-25. doi:10.1007/s40261-015-0336-0

83. Guanfacine. In: *LiverTox: Clinical and Research Information on Drug-Induced Liver Treatment*. <https://www.ncbi.nlm.nih.gov/books/NBK548586/>.
84. Hervas A, Huss M, Johnson M, et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. *Eur Neuropsychopharmacol*. 2014;24(12):1861-1872. doi:10.1016/j.euroneuro.2014.09.014
85. Anand S, Tong H, Besag FMC, Chan EW, Cortese S, Wong ICK. Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with Attention-Deficit/Hyperactivity Disorder: A Systematic Review with Methodological Quality Assessment. *Paediatr Drugs*. 2017;19(3):235-250. doi:10.1007/s40272-017-0224-6
86. Ming X, Mulvey M, Mohanty S, Patel V. Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders. *Adolesc Health Med Ther*. 2011;2:105-112. doi:10.2147/AHMT.S15672
87. Joo SW, Kim H-W. Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder and/or Tourette's Disorder with Clonidine Extended Release. *Psychiatry Investig*. 2018;15(1):90-93. doi:10.4306/pi.2018.15.1.90
88. Label: Kapvay-clonidine hydrochlorine tablet, extended release. U.S. National Library of Medicine. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa7700e2-ae5d-44c4-a609-76de19c705a7>. Published 2020. Accessed April 11, 2020.
89. Vaidyanathan S, Rajan TM, Chandrasekaran V, Kandasamy P. Pre-school attention deficit hyperactivity disorder: 12 weeks prospective study. *Asian J Psychiatr*. 2020;48:101903. doi:10.1016/j.ajp.2019.101903
90. Strange BC. Once-daily treatment of ADHD with guanfacine: patient implications. *Neuropsychiatr Dis Treat*. 2008;4(3):499-506. doi:10.2147/ndt.s1711
91. Popper CW. Antidepressants in the treatment of attention-deficit/hyperactivity disorder. *J Clin Psychiatry*. 1997;58 Suppl 1:11-14.
92. Verbeeck W, Tuinier S, Bekkering GE. Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review. *Adv Ther*. 2009;26(2):170-184. doi:10.1007/s12325-009-0008-7

93. Biederman J, Spencer T, Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. *Int J Neuropsychopharmacol*. 2004;7(1):77-97. doi:10.1017/S1461145703003973
94. Rowles BM, Findling RL. Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders. *Dev Disabil Res Rev*. 2010;16(3):273-282. doi:10.1002/ddrr.120
95. Stubberfield, TG, Wray, JA, Parry T. Utilization of alternative therapies in attention-deficit hyperactivity disorder. *J Pediatr Child Heal*. 1999;35(5):450-453.
96. Ahn J, Ahn HS, Cheong JH, Dela Pena I. Natural Product-Derived Treatments for Attention-Deficit/Hyperactivity Disorder: Safety, Efficacy, and Therapeutic Potential of Combination Therapy. *Neural Plast*. 2016;2016:1320423. doi:10.1155/2016/1320423
97. Owens JA. A clinical overview of sleep and attention-deficit/hyperactivity disorder in children and adolescents. *J Can Acad Child Adolesc Psychiatry*. 2009;18(2):92-102.
98. Um YH, Hong S-C, Jeong J-H. Sleep problems as predictors in attention- hyperactivity disorder: causal mechanisms, consequences and treatment. *Clin Psychopharmacol Neurosci*. 2017;15(1):9-18. doi:10.9758/cpn.2017.15.1.9
99. McGough JJ, Sturm A, Cowen J, et al. Double-Blind, Sham-Controlled, Pilot Study of Trigeminal Nerve Stimulation for Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry*. 2019;58(4):403-411.e3. doi:10.1016/j.jaac.2018.11.013
100. Darling KA, Eggleston MJF, Retallick-Brown H, Rucklidge JJ. Mineral-Vitamin Treatment Associated with Remission in Attention-Deficit/Hyperactivity Disorder Symptoms and Related Problems: 1-Year Naturalistic Outcomes of a 10-Week Randomized Placebo-Controlled Trial. *J Child Adolesc Psychopharmacol*. July 2019. doi:10.1089/cap.2019.0036
101. Ragav, S, Singh, H, Dalal P. Randomized controlled trial of standardized Bacopa monniera extract in age-associated memory impairment. *Indian J Psychiatry*. 2006;48(4):238-242.
102. Roodenrys S, Booth D, Bulzomi S, Phipps A, Micallef C, Smoker J. Chronic effects of Brahmi (Bacopa monnieri) on human memory. *Neuropsychopharmacology*. 2002;27(2):279-281. doi:10.1016/S0893-133X(01)00419-5

103. Pham HTN, Phan SV, Tran HN, et al. Bacopa monnieri (L.) Ameliorates Cognitive Deficits Caused in a Trimethyltin-Induced Neurotoxicity Model Mice. *Biol Pharm Bull.* 2019;42(8):1384-1393. doi:10.1248/bpb.b19-00288
104. Piyabhan P, Wetchateng T. Bacopa monnieri (Brahmi) Enhanced Cognitive Function and Prevented Cognitive Impairment by Increasing VGLUT2 Immunodensity in Prefrontal Cortex of Sub-Chronic Phencyclidine Rat Model of Schizophrenia. *J Med Assoc Thai.* 2015;98 Suppl 3:S7-15.
105. Abdul Manap AS, Vijayabalan S, Madhavan P, et al. Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies. *Drug Target Insights.* 2019;13:1177392819866412. doi:10.1177/1177392819866412
106. Mishra M, Mishra AK, Mishra U. Brahmi (Bacopa monnieri Linn) in the treatment of dementias - a pilot study. *Futur Healthc J.* 2019;6(Suppl 1):69. doi:10.7861/futurehosp.6-1-s69
107. Jauhari, N, Singh, YD, Kushwaha, KP, Rastogi, CK, Asthana, OP, Srivastava, JS, Rathi A. Clinical evaluation of bacopa monniera extract n behavioral and cognitive functions in children suffering from attention deficit hypersensitivity disorder. 2001.
108. Sukumaran NP, Amalraj A, Gopi S. Neuropharmacological and cognitive effects of Bacopa monnieri (L.) Wettst - A review on its mechanistic aspects. *Complement Ther Med.* 2019;44:68-82. doi:10.1016/j.ctim.2019.03.016
109. Effatpanah M, Rezaei M, Effatpanah H, et al. Magnesium status and attention deficit hyperactivity disorder (ADHD): A meta-analysis. *Psychiatry Res.* 2019;274:228-234. doi:10.1016/j.psychres.2019.02.043
110. Huang D, Hu Z, Yu Z. Eleutheroside B or E enhances learning and memory in experimentally aged rats. *Neural Regen Res.* 2013;8(12):1103-1112. doi:10.3969/j.issn.1673-5374.2013.12.005
111. Starobrat-Hermelin B, Koziellec T. The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD). Positive response to magnesium oral loading test. *Magnes Res.* 1997;10(2):149-156.
112. Wang L-J, Yang C-Y, Chou W-J, et al. Gut microbiota and dietary patterns in children with attention-deficit/hyperactivity disorder. *Eur Child Adolesc Psychiatry.* May 2019. doi:10.1007/s00787-019-01352-2

113. Kozielic, T, Starobrat-Hermelin B. Assessment of magnesium levels in children with attention deficit hyperactivity disorder (ADHD). *Magnes Res.* 1997;10(2):143-148.
114. Mousain-Bosc, M, Roche, M, Rapin, J, Bali J. Improvement of neurobehavioral disorders in children supplemented with magnesium - vitamin B6. *Magnes Res.* 2006;19:46-52.
115. Mousain-Bosc M, Roche M, Rapin J, Bali J-P. Magnesium VitB6 intake reduces central nervous system hyperexcitability in children. *J Am Coll Nutr.* 2004;23(5):545S-548S.
116. Dolina S, Margalit D, Malitsky S, Rabinkov A. Attention-deficit hyperactivity disorder (ADHD) as a pyridoxine-dependent condition: urinary diagnostic biomarkers. *Med Hypotheses.* 2014;82(1):111-116. doi:10.1016/j.mehy.2013.11.018
117. Sahin N, Altun H, Kurutas EB, Balkan D. Vitamin D and vitamin D receptor levels in children with attention-deficit/hyperactivity disorder. *Neuropsychiatr Dis Treat.* 2018;14:581-585. doi:10.2147/NDT.S158228
118. Seyedi M, Gholami F, Samadi M, et al. The Effect of Vitamin D3 Supplementation on Serum BDNF, Dopamine and Serotonin in Children with Attention-Deficit/Hyperactivity Disorder. *CNS Neurol Disord Drug Targets.* July 2019. doi:10.2174/1871527318666190703103709
119. Eishorbagy, HH, Barseem, NF, Abdelghani W. Impact of vitamin D supplementation on attention-deficit hyperactivity disorder in children. *Ann Pharmacother.* 2018;52(7):623-631.
120. Dehbokri N, Noorazar G, Ghaffari A, Mehdizadeh G, Sarbakhsh P, Ghaffary S. Effect of vitamin D treatment in children with attention-deficit hyperactivity disorder. *World J Pediatr.* November 2018. doi:10.1007/s12519-018-0209-8
121. Gan J, Galer P, Ma D, Chen C, Xiong T. The Effect of Vitamin D Supplementation on Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Child Adolesc Psychopharmacol.* August 2019. doi:10.1089/cap.2019.0059
122. Kimura K, Ozeki M, Juneja LR, Ohira H. L-Theanine reduces psychological and physiological stress responses. *Biol Psychol.* 2007;74(1):39-45. doi:10.1016/j.biopsycho.2006.06.006
123. Haskell CF, Kennedy DO, Milne AL, Wesnes KA, Scholey AB. The effects of L-theanine,

- caffeine and their combination on cognition and mood. *Biol Psychol.* 2008;77(2):113-122. doi:10.1016/j.biopsycho.2007.09.008
124. Kobayashi, K, Nagato, Y, Aoi N. Effects of L-theanine on the release of alpha-brain waves in human volunteers. *Nippon NOgeikagaku Kaishi.* 1998;72:153-157.
 125. Mason R. 200 mg of zen: L-theanine boosts alpha waves, promotes alert relaxation. *Altern Complem Ther.* 2001;7:91-95.
 126. Lyon MR, Kapoor MP, Juneja LR. The effects of L-theanine (Suntheanine(R)) on objective sleep quality in boys with attention deficit hyperactivity disorder (ADHD): a randomized, double-blind, placebo-controlled clinical trial. *Altern Med Rev.* 2011;16(4):348-354.
 127. Busserolles J, Gueux E, Balasinska B, et al. In vivo antioxidant activity of procyanidin-rich extracts from grape seed and pine (*Pinus maritima*) bark in rats. *Int J Vitam Nutr Res.* 2006;76(1):22-27. doi:10.1024/0300-9831.76.1.22
 128. Bagchi D, Bagchi M, Stohs SJ, et al. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. *Toxicology.* 2000;148(2-3):187-197.
 129. Uchida S. Condensed tannins scavenging activity of oxygen radicals. *Med Sci Res.* 1980;15:831-832.
 130. Sezen H, Kandemir H, Savik E, et al. Increased oxidative stress in children with attention deficit hyperactivity disorder. *Redox Rep.* 2016;21(6):248-253. doi:10.1080/13510002.2015.1116729
 131. Guney E, Cetin FH, Alisik M, et al. Attention Deficit Hyperactivity Disorder and oxidative stress: A short term follow up study. *Psychiatry Res.* 2015;229(1-2):310-317. doi:10.1016/j.psychres.2015.07.003
 132. Fluegge K. Environmental factors influencing the link between childhood ADHD and risk of adult coronary artery disease. *Med Hypotheses.* 2018;110:83-85.
 133. Kar P, Laight D, Shaw KM, Cummings MH. Flavonoid-rich grape seed extracts: a new approach in high cardiovascular risk patients? *Int J Clin Pract.* 2006;60(11):1484-1492. doi:10.1111/j.1742-1241.2006.01038.x
 134. Perez-Jimenez J, Saura-Calixto F. Grape products and cardiovascular disease risk

- factors. *Nutr Res Rev.* 2008;21(2):158-173. doi:10.1017/S0954422408125124
135. Levine M, Padayatty SJ, Espey MG. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. *Adv Nutr.* 2011;2(2):78-88. doi:10.3945/an.110.000109
 136. Moser MA, Chun OK. Vitamin C and Heart Health: A Review Based on Findings from Epidemiologic Studies. *Int J Mol Sci.* 2016;17(8). doi:10.3390/ijms17081328
 137. Lynch SM, Gaziano JM, Frei B. Ascorbic acid and atherosclerotic cardiovascular disease. *Subcell Biochem.* 1996;25:331-367.
 138. Tseng P-T, Cheng Y-S, Yen C-F, et al. Peripheral iron levels in children with attention-deficit hyperactivity disorder: a systematic review and meta-analysis. *Sci Rep.* 2018;8(1):788. doi:10.1038/s41598-017-19096-x
 139. Doom JR, Georgieff MK, Gunnar MR. Institutional care and iron deficiency increase ADHD symptomology and lower IQ 2.5-5 years post-adoption. *Dev Sci.* 2015;18(3):484-494. doi:10.1111/desc.12223
 140. Doom JR, Richards B, Caballero G, Delva J, Gahagan S, Lozoff B. Infant Iron Deficiency and Iron Supplementation Predict Adolescent Internalizing, Externalizing, and Social Problems. *J Pediatr.* 2018;195:199-205.e2. doi:10.1016/j.jpeds.2017.12.008
 141. Konofal E, Lecendreux M, Arnulf I, Mouren M-C. Iron deficiency in children with attention-deficit/hyperactivity disorder. *Arch Pediatr Adolesc Med.* 2004;158(12):1113-1115. doi:10.1001/archpedi.158.12.1113
 142. Permuy M, Guede D, Lopez-Pena M, Munoz F, Caeiro J-R, Gonzalez-Cantalapiedra A. Comparison of various SYSADOA for the osteoarthritis treatment: an experimental study in rabbits. *BMC Musculoskelet Disord.* 2015;16:120. doi:10.1186/s12891-015-0572-8
 143. Didriksen M et al. Self-reported restless legs syndrome and involuntary leg movements during sleep are associated with symptoms of attention deficit hyperactivity disorder. *Sleep Med.* 2019.
 144. Lange KW, Hauser J, Lange KM, et al. The Role of Nutritional Supplements in the Treatment of ADHD: What the Evidence Says. *Curr Psychiatry Rep.* 2017;19(2):8. doi:10.1007/s11920-017-0762-1

145. Sever Y, Ashkenazi A, Tyano S, Weizman A. Iron treatment in children with attention deficit hyperactivity disorder. A preliminary report. *Neuropsychobiology*. 1997;35(4):178-180. doi:10.1159/000119341
146. Konofal E, Lecendreux M, Deron J, et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. *Pediatr Neurol*. 2008;38(1):20-26. doi:10.1016/j.pediatrneurol.2007.08.014
147. Kennedy DO, Scholey AB. The psychopharmacology of European herbs with cognition-enhancing properties. *Curr Pharm Des*. 2006;12(35):4613-4623.
148. Kennedy DO, Little W, Scholey AB. Attenuation of laboratory-induced stress in humans after acute administration of *Melissa officinalis* (Lemon Balm). *Psychosom Med*. 2004;66(4):607-613. doi:10.1097/01.psy.0000132877.72833.71
149. Kennedy, DO, Wake, G, Savelev, S, Tildesley, NTJ, Perry, EK, Wesnes, KA, Scholey A. Modulation of mood and cognitive performance following acute administration of single doses of *Melissa officinalis* (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. *Neuropsychopharmacology*. 2003;28:1871-1881.
150. Cases J, Ibarra A, Feuillere N, Roller M, Sukkar SG. Pilot trial of *Melissa officinalis* L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. *Med J Nutrition Metab*. 2011;4(3):211-218. doi:10.1007/s12349-010-0045-4
151. Costello RB, Lentino C V, Boyd CC, et al. The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment of the literature. *Nutr J*. 2014;13:106. doi:10.1186/1475-2891-13-106
152. van Maanen A, Meijer AM, Smits MG, Oort FJ. Classical conditioning for preserving the effects of short melatonin treatment in children with delayed sleep: a pilot study. *Nat Sci Sleep*. 2017;9:67-79. doi:10.2147/NSS.S129203
153. Van der Heijden KB, Smits MG, Van Someren EJW, Ridderinkhof KR, Gunning WB. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. *J Am Acad Child Adolesc Psychiatry*. 2007;46(2):233-241. doi:10.1097/01.chi.0000246055.76167.0d
154. Hoebert M, van der Heijden KB, van Geijlswijk IM, Smits MG. Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia. *J Pineal Res*. 2009;47(1):1-7. doi:10.1111/j.1600-079X.2009.00681.x

155. Smits MG, Nagtegaal EE, van der Heijden J, Coenen AM, Kerkhof GA. Melatonin for chronic sleep onset insomnia in children: a randomized placebo-controlled trial. *J Child Neurol.* 2001;16(2):86-92. doi:10.1177/088307380101600204
156. Dodig-Curkovic K, Dovhanj J, Curkovic M, Dodig-Radic J, Degmecic D. [The role of zinc in the treatment of hyperactivity disorder in children]. *Acta Med Croatica.* 2009;63(4):307-313.
157. Akhondzadeh S, Mohammadi M-R, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. *BMC Psychiatry.* 2004;4:9. doi:10.1186/1471-244X-4-9
158. Arnold LE, Disilvestro RA, Bozzolo D, et al. Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. *J Child Adolesc Psychopharmacol.* 2011;21(1):1-19. doi:10.1089/cap.2010.0073
159. Baziar S, Aqamolaei A, Khadem E, et al. Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study. *J Child Adolesc Psychopharmacol.* February 2019. doi:10.1089/cap.2018.0146
160. Liebert MA. Could saffron be as effective as stimulant medicines in treating ADHD? EurekaAlert. https://www.eurekaalert.org/pub_releases/2019-02/mali-csb022119.php. Published 2019. Accessed March 8, 2019.
161. Agostoni C, Nobile M, Ciappolino V, et al. The Role of Omega-3 Fatty Acids in Developmental Psychopathology: A Systematic Review on Early Psychosis, Autism, and ADHD. *Int J Mol Sci.* 2017;18(12). doi:10.3390/ijms18122608
162. Lopez-Vicente M, Ribas Fito N, Vilor-Tejedor N, et al. Prenatal Omega-6:Omega-3 Ratio and Attention Deficit and Hyperactivity Disorder Symptoms. *J Pediatr.* 2019;209:204-211.e4. doi:10.1016/j.jpeds.2019.02.022
163. Chang, J, Su, K, Modelli, V, & Pariante C. Omega-3 fatty acids improve attention in youth with attention deficit disorder. *Brain, Behav Immun.* 2019:e25.
164. Manor I, Magen A, Keidar D, et al. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. *Eur Psychiatry.* 2012;27(5):335-342. doi:10.1016/j.eurpsy.2011.05.004

165. Derbyshire E. Do Omega-3/6 Fatty Acids Have a Therapeutic Role in Children and Young People with ADHD? *J Lipids*. 2017;2017:6285218. doi:10.1155/2017/6285218
166. Konigs A, Kiliaan AJ. Critical appraisal of omega-3 fatty acids in attention-deficit/hyperactivity disorder treatment. *Neuropsychiatr Dis Treat*. 2016;12:1869-1882. doi:10.2147/NDT.S68652
167. Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. *J Am Acad Child Adolesc Psychiatry*. 2011;50(10):991-1000. doi:10.1016/j.jaac.2011.06.008
168. Bos DJ, Oranje B, Veerhoek ES, et al. Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder. *Neuropsychopharmacology*. 2015;40(10):2298-2306. doi:10.1038/npp.2015.73
169. Hirayama S, Terasawa K, Rabeler R, et al. The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial. *J Hum Nutr Diet*. 2014;27 Suppl 2:284-291. doi:10.1111/jhn.12090
170. Thapar A, Cooper M. Attention deficit hyperactivity disorder. *Lancet (London, England)*. 2016;387(10024):1240-1250. doi:10.1016/S0140-6736(15)00238-X